Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Ensysce Biosciences, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +3 vs. Q1 2026
- Shares held
- 904.7K
- +417.7K (+85.8%) vs. Q1 2026
- Total value
- $261.1K
- −$430 (−0.2%) vs. Q1 2026
- New holders
- 5
- 5 more added
- Sold out
- 2
- 1 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $832.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 208,833 | $60.6K | 0.00% | +195,263+1,438.9% | Added |
| Adage Capital Partners GP, L.L.C. | 149,711 | $43.4K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 95,391 | $28.0K | 0.00% | +82,078+616.5% | Added |
| Perceptive Advisors LLC | 86,666 | $25.1K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 86,193 | $25.0K | 0.00% | +28,830+50.3% | Added |
| XTX Topco Ltd | 77,005 | $22.3K | 0.00% | +52,642+216.1% | Added |
| Geode Capital Management, LLC | 62,188 | $18.0K | 0.00% | −11,692−15.8% | Reduced |
| HRT Financial LP | 54,429 | $15.0K | 0.00% | +54,429 | New |
| Susquehanna International Group, LLP | 34,280 | $9.94K | 0.00% | +34,280 | New |
| Tru Independence Asset Management 2, LLC | 13,000 | $3.77K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 12,953 | $3.76K | 0.00% | +12,953 | New |
| Vanguard Capital Management LLC | 12,854 | $3.73K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,094 | $1.77K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 1,440 | $418 | 0.00% | +1,440 | New |
| SBI Securities Co., Ltd. | 641 | $186 | 0.00% | +155+31.9% | Added |
| BlackRock, Inc. | 65 | $19 | 0.00% | 00.0% | Unchanged |
| FNY Investment Advisers, LLC | 3,000 | $0 | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 1 | $0 | 0.00% | +1 | New |
| Vanguard Fiduciary Trust Co | 0 | $0 | 0.00% | −23,854−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −8,791−100.0% | Sold out |